Ph.D., Vice President of Translational Biology, Biogen Inc.
Sally is a Vice President of Translational Biology within the R&D at Biogen. Her group provides in-vivo and in-vitro models, technologies and analytics to support the discovery and development from identification of new targets through to understanding genetic variability in drug response and patient stratification.. Sally is a passionate advocate of the value of human genetics to support early drug discovery and is an active champion of open innovation and collaboration in the field of genomic and contributes to and organizes events aimed at fostering a deeper interaction between academia and industry. Prior to joining Biogen in 2014, she was Head of Clinical Genetics and Bioinformatics at Pfizer. She gained a Ph.D. in Molecular Biology from the University of Manchester, UK. She began her academic career studying the genetic basis of rheumatoid arthritis, focusing on genomic analysis in the context of epidemiological studies.